Merck to work with IAVI on coronavirus vaccine

Tuesday, 26. May 2020 13:29

Merck, one of the most prominent pharmaceutical companies in the United States, announced on Tuesday they will be working with the non-profit scientific research organization IAVI on the development of a coronavirus vaccine.

Merck and IAVI said in their joint statement they would use the recombinant vesicular stomatitis virus (rVSV) technology previously used for the development of the Ebola Zaire virus vaccine to try to produce a vaccine that would be effective against COVID-19.

Should their vaccine prove effective, Merck said they would "make it accessible and affordable" worldwide. Merck shares were up 3.12% in premarket trade on Wall Street.

Related Links: 
Author:
Breaking the News / JR